MRCF has reached the first close of a CSL-backed fifth fund to make early-stage investments in medical technologies in Australia and New Zealand.
Australian government-backed healthcare investment vehicle Medical Research Commercialisation Fund (MRCF) has raised A$210m ($148m) from limited partners including biotech producer CSL for its fifth fund.
The capital represents the fund’s first close and its LPs also include the rest of MRCF’s existing investors: the Australian government and pension fund managers AustralianSuper, Hesta, Statewide and Hostplus.
Like its predecessors, MRCF5 will be managed by venture capital firm Brandon Capital Partners, which is now courting select institutional investors for a targeted final…
